key: cord-0842814-g660pldw
authors: Sil, A.; Panigrahi, A.; Chandra, A.; Pramanik, J.D.
title: ‘COVID nose’ – A unique post–COVID pigmentary sequelae reminiscing Chik sign: A descriptive case series
date: 2022-02-16
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.17989
sha: 1979b70d1517f191d687b2ec59fdb34d94f92f61
doc_id: 842814
cord_uid: g660pldw

nan

Six patients presented to our dedicated post-COVID clinic over the course of this pandemic with facial pigmentation (Table 1) . Institutional Ethics Committee approval and written informed consent from all these patients were obtained. They comprised of four females and two males (age range: 25-65 years, mean: 44 years). Accompanying comorbidity (diabetes mellitus-1, hypothyroidism and COPD-1) was noted in two patients (33%). History regarding medications, pre-existing dermatoses and arthritis was not elicited in any patient. Apart from the aesthetic disturbance owing to pigmentation, the condition was asymptomatic in majority of patients (5, 83%). All patients had experienced only mild COVID-19 symptoms, from which they had recovered with standard supportive care without any systemic complications. The interval between onset of COVID-19 symptoms and appearance of nasal pigmentation ranged from 15-27 days (mean 23.2 days). On cutaneous assessment, multiple discrete and few coalescing dark brown-to-black freckle-like macules was observed to be localized mainly over the tip and ala nose in most cases (100%) with occasional involvement of malar area (2, 33%) (Fig. 1a-c) . Dermoscopy [DermLite DL4, contact/ polarized, 109] revealed areas of light-to-dark brown reticular pigment network over light brown background with perifollicular pigment clumping (Fig. 1d) Histopathological examination could not be carried out as the patients refused consent for biopsy. Routine blood parameters was within normal levels and serological tests for dengue and chikungunya viruses was negative. Treatment with topical skin-lightening agents (azelaic acid and hydroquinone) coupled with sunscreen led to significant resolution of pigmentation in 10-16 weeks.

Pigmentary alteration has rarely been directly attributed to SARS-CoV-2. 1 In China, there were televised reports of two COVID-19 affected physicians who developed darkening of skin. The cause was subsequently found to be iatrogenicpolymixin B was prescribed to both patients to treat multidrug resistant bacterial infection. 2 The localized hyperpigmentation involving the centrofacial area that we observed in our patients was reminiscent of the 'Chik sign'. 3 In resource-limited settings, this classic pigmentary sequelae serves a cutaneous clue in making a retrospective diagnosis of chikungunya fever and rarely dengue. 4, 5 The underlying pathology remains speculative. On histopathology, increased basal layer pigmentation, pigmentary incontinence and dermal melanophages with perivascular inflammatory infiltration have been observed. Thus, an increased intraepidermal melanin dispersion/retention triggered by the virus has been postulated as a cause for pigmentation. 6 Predominant affection of the centrofacial area indicates the possible role of ultraviolet radiation exposure in this patterned distribution of pigmentation. As a postviral event, this mechanistic reasoning may explain the pigmentary outcome in SARS-CoV-2-infected patients. Interestingly, accompanying postfebrile arthritis is a feature common to both the viral aetiologies (SARS-CoV-2 and chikungunya). 7 Thus, making a serological diagnosis is imperative in such cases. After excluding the common causes and given the temporal relation with COVID-19, the cause of the nasal pigmentation in these patients was attributed to SARS-CoV-2 infection. Hyperpigmentation associated with chikungunya fever (CF) usually develop after 1-3 weeks after fever defervescence. 6, 8 In our set of patients, a slightly longer time gap was noted. Therapeutic measures like photo-protection, sunscreen and topical usage of hypopigmenting agents of hydroquinone cream with or without short course topical steroids for a month have shown good response in treating hyperpigmentation in CF patients. 4, 9 For our patients, we had to continue topical therapy for nearly 3-4 months for clinical improvement to be appreciable.

In conclusion, we highlight here a unique series of patients where a pigmentary sequelae ('COVID nose') was directly ascribed to COVID-19. 'Chik sign', which is considered a feature quite unique to CF, should also raise the suspicion of a preceding COVID-19 infection. We further implore clinicians to broaden the list of differentials for this presentation to include other viral aetiologies.

Dermatological manifestations associated with COVID-19 infection

Skin hyperpigmentation in coronavirus disease 2019 patients: is polymyxin B the culprit?

Cutaneous signs in infectious diseases

Chik sign in chikungunya fever

The chik sign in dengue

Post-chikungunya hyperpigmentation

Post-COVID-19 arthritis: a case report and literature review

Cutaneous manifestations of chikungunya during a recent epidemic in Calicut, north Kerala, south India

Hyperpigmentation and chikungunya fever

The patients in this manuscript have given written informed consent to publication of their case details.

None.

None.

The data that support the findings of this study are available from the corresponding author upon reasonable request.A. Sil